For over a decade, gemcitabine plus cisplatin has been an established first-line systemic treatment for patients with locally advanced/metastatic disease, although recent data indicate that the addition of anti-programmed cell death ligand-1 (PD-L1) therapy further improves outcomes3,4. Here, CD274 is linked to metastatic neoplasm.